MedPage Today (2/14, George) reports, “Concerns about Alzheimer’s disease were high, but knowledge about aducanumab (Aduhelm) was low, survey data” revealed. The data found that “among 1,035 older Americans surveyed during a period when media coverage of the FDA’s controversial approval of aducanumab was high, 84.9% said they were concerned about Alzheimer’s disease.” However, 73.2% “said they knew nothing about aducanumab, and 26.8% said they knew ‘just some’ or ‘a fair amount’ about the” medication. The findings were published online in a research letter in JAMA Network Open. (SOURCE: APA Headlines)